AmerisourceBergen Corporation (ABC:NYSE):

09/10/2001- "Announces Conference Call and Webcast For Today"

09/10/2001- "Provides Update on Integration Plans"

08/29/2001- "Merges With Bergen Brunswig To Create New Industry Leader,                         AmerisourceBergen"

08/28/2001- "Added To S&P 500 Index"

Announces Conference Call and Webcast For Today

VALLEY FORGE, Pa.--Sept. 10, 2001--AmerisourceBergen Corporation (NYSE:ABC) today announced that the Company will host an investor conference call and webcast at 12:45 pm Eastern Daylight Time today, Monday, September 10, 2001. Participating in the conference call will be R. David Yost, President and Chief Executive Officer; Kurt J. Hilzinger, Executive Vice President and Chief Operating Officer; and Neil F. Dimick, Executive Vice President and Chief Financial Officer. The conference call will address the strategic direction for the Company, its integration planning and a financial review. To access the live conference call via telephone: Dial in: 800-230-1096 from inside the U.S. no access code required 612-332-0636 from outside the U.S. no access code required To access the live webcast: Go to the Quarterly

Webcasts section on the Investor Relations page at http://www.amerisourcebergen.net A replay of the call and webcast will be available from 5:15 pm September 10, 2001 until 11:59 pm September 17, 2001. To access the replay via telephone: Dial in: 800-475-6701 from within the U.S., access code: 602171 320-365-3844 from outside the U.S., access code: 602171

To access the archived webcast: Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.net

About AmerisourceBergen

AmerisourceBergen (NYSE:ABC) is the largest pharmaceutical services company in the United States dedicated solely to the pharmaceutical supply chain. It is the leading distributor of pharmaceutical products and services to the hospital systems/acute care market, alternative care facilities, and independent community pharmacies. The Company is also a leader in the institutional pharmacy marketplace. With approximately $36 billion in annualized operating revenues, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people serving over 25,000 customers.

FORWARD-LOOKING STATEMENTS

This press release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include statements addressing future financial and operating results of AmerisourceBergen and the benefits and other aspects of the merger. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the risk that the businesses of AmeriSource and Bergen Brunswig will not be integrated successfully; failure to obtain and retain expected synergies; and other economic, business, competitive and/or regulatory factors affecting the business of AmerisourceBergen generally. More detailed information about these factors is set forth in AmeriSource's and Bergen Brunswig's filings with the Securities and Exchange Commission, including each of their Annual Reports on Form 10-K for fiscal 2000, their most recent quarterly reports on Form 10-Q, and their joint proxy statement-prospectus dated August 1, 2001. AmerisourceBergen, AmeriSource and Bergen Brunswig are under no obligation to (and expressly disclaim any such obligation to) update or alter their forward-looking statements whether as a result of new information, future events or otherwise.

Return to headlines

Provides Update on Integration Plans

VALLEY FORGE, Pa.--Sept. 10, 2001--AmerisourceBergen Corporation (NYSE:ABC) today announced an overview of its strategic plan to integrate the operations of AmeriSource Health Corporation and Bergen Brunswig Corporation.

The Company also provided updated financial guidance for AmerisourceBergen. The merger of AmeriSource and Bergen Brunswig, two leading pharmaceutical services companies, was completed on August 29, 2001.

AmerisourceBergen said it expects to achieve $150 million in annual synergies within three years, with the majority of the savings occurring in years two and three. The savings are expected to come from consolidation of distribution centers ($50 million), enhanced efficiency of distribution facilities ($30 million), procurement ($30 million), administration and information technology ($35 million), and $5 million in other savings.

The integration strategy has three phases. Upon completion, the Company expects to have approximately 30 distribution centers, down from 51 today. Approximately four to six distribution facilities are expected to be closed in the first year. In addition, four-to-eight new facilities will be built.

Financial Guidance

AmerisourceBergen said its long-term financial goals are: Revenue growth of at least 15% Earnings before interest and taxes growth of at least 15% Earnings per share growth of at least 20%, before merger and acquisition costs Return on committed capital of at least 20% in each business segment The Company said it expects to incur $10 million to $15 million of merger-related costs in the September quarter of fiscal 2001. AmerisourceBergen also said the elimination of goodwill under new accounting rules adds $0.13 to $0.14 to earnings per share in fiscal 2002.

"This is an exciting time for AmerisourceBergen as we hit the ground running," said David Yost, President and Chief Executive Officer. "We see tremendous potential for the new AmerisourceBergen in terms of providing enhanced services for customers and suppliers. Our updated financial guidance, including the goal of a 20% increase in EPS before merger costs, reflects the strategic strength of our combined company as well as the substantial opportunities for us in this $160 billion market." Mr. Yost continued, "Our integration planning is on track. Our thorough review of the synergy opportunities has also enabled us to increase our expectations to $150 million in annual synergies by the end of the third year. The consolidation strategy we are executing truly brings together the best of both companies, including a regional organization structure with empowered local management."

Management of AmerisourceBergen will today outline the Company's strategic direction, integration plans and financial review during a conference call for investors. The call will be webcast beginning at 12:45 pm Eastern Daylight Time today/ To access the live conference call via telephone: Dial in: 800-230-1096 from inside the U.S. no access code required 612-332-0636 from outside the U.S. no access code required To access the live webcast: Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.net A replay of the call and webcast will be available from 5:15 pm September 10, 2001 until 11:59 pm September 17, 2001.

To access the replay via telephone: Dial in: 800-475-6701 from within the U.S., access code: 602171 320-365-3844 from outside the U.S., access code: 602171 To access the archived webcast: Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.net

About AmerisourceBergen

AmerisourceBergen (NYSE:ABC) is the largest pharmaceutical services company in the United States dedicated solely to the pharmaceutical supply chain. It is the leading distributor of pharmaceutical products and services to the hospital systems/acute care market, alternative care facilities, and independent community pharmacies. The Company is also a leader in the institutional pharmacy marketplace. With approximately $36 billion in annualized operating revenues, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people serving over 25,000 customers.

Forward-Looking Statements

This press release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include statements addressing future financial and operating results of AmerisourceBergen and the benefits and other aspects of the merger. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the risk that the businesses of AmeriSource and Bergen Brunswig will not be integrated successfully; failure to obtain and retain expected synergies; and other economic, business, competitive and/or regulatory factors affecting the business of AmerisourceBergen generally. More detailed information about these factors is set forth in AmeriSource's and Bergen Brunswig's filings with the Securities and Exchange Commission, including each of their Annual Reports on Form 10-K for fiscal 2000, their most recent quarterly reports on Form 10-Q, and their joint proxy statement-prospectus dated August 1, 2001. AmerisourceBergen, AmeriSource and Bergen Brunswig are under no obligation to (and expressly disclaim any such obligation to) update or alter their forward-looking statements whether as a result of new information, future events or otherwise.

Return to headlines

Merges With Bergen Brunswig To Create New Industry Leader, AmerisourceBergen

VALLEY FORGE, Pa.--Aug. 29, 2001-- Combination Creates Leader In Pharmaceutical Supply Chain Management New NYSE Trading Symbol is "ABC"

AmerisourceBergen Corporation today announced that AmeriSource Health Corporation and Bergen Brunswig Corporation have completed their merger of equals to form a new company,

AmerisourceBergen Corporation.

The Company is a new leader in U.S. pharmaceutical services with approximately $36 billion in annualized operating revenues. Headquartered in Valley Forge, Pennsylvania, the new company will begin trading under the symbol "ABC," tomorrow, August 30, 2001, on the New York Stock Exchange. AmeriSource and Bergen Brunswig shareholders approved the merger during independent meetings held earlier today. Under the terms of the merger agreement, each share of Bergen Brunswig common stock was converted into 0.37 of a share of AmerisourceBergen common stock and each share of AmeriSource common stock was converted into one share of AmerisourceBergen common stock.

The new Company will have approximately 103 million shares outstanding.

"The creation of AmerisourceBergen signals the arrival of a new leader in pharmaceutical services, a company that will be more than the sum of its parts," said Robert E. Martini, Chairman of AmerisourceBergen. "Built on a foundation of superior customer service, the new company will combine the best people, the best operations and the best programs to deliver a new level of value to every step of the pharmaceutical supply chain."

R. David Yost, AmerisourceBergen's President and Chief Executive Officer, said, "The resources and people of this new Company will allow us to establish a new model in the pharmaceutical supply chain. Anchored in exceptional customer service, we will build shareholder value by delivering pharmaceutical and healthcare products, services and solutions in innovative and cost effective ways. Our single focus on pharmaceutical services will provide the best service in the pharmaceutical supply chain with improved operational efficiencies and expanded offerings and programs."

Board of Directors

AmerisourceBergen also named six new members to its Board of Directors. AmeriSource designated three of the new directors, each from the previous AmeriSource Board. They are: Richard C. Gozon, Executive Vice President, Weyerhaeuser Company; Edward E. Hagenlocker, Retired Vice Chairman, Ford Motor Company; and J. Lawrence Wilson, Retired Chairman and Chief Executive Officer, Rohm and Haas Company.

Bergen Brunswig also designated three new directors, each from the previous Bergen Brunswig Board. They are: Rodney H. Brady, President and Chief Executive Officer, Deseret Management Corporation; James R. Mellor, Chairman of the Board, USEC, Inc. and Former Chairman of the Board and Chief Executive Officer, General Dynamics Corporation; and Francis G. Rodgers, Author and Lecturer and Former Vice President, Marketing, IBM.

Mr. Martini and Mr. Yost were previously appointed members of the new Board. In addition, two unaffiliated directors will be named in the near future.

Management

In addition to Mr. Yost, the senior management of AmerisourceBergen includes Kurt J. Hilzinger, Executive Vice President and Chief Operating Officer, and Neil F. Dimick, Executive Vice President and Chief Financial Officer.

The senior management also includes three Senior Vice Presidents. They are Brent R. Martini, President of AmerisourceBergen Drug Company; Charles J. Carpenter, President of PharMerica; and Steven H. Collis, President of ASD Specialty Healthcare, Inc. Synergies

As announced earlier, AmerisourceBergen expects to achieve $125 million in annual pre-tax operating savings by the end of the third anniversary of the merger. The savings will come primarily from reducing the number of distribution centers from the current 51 to approximately 30, consolidation of corporate staffs, and efficiencies in purchasing.

Said Mr. Yost, "We have done a significant amount of work over the last five months evaluating operational and corporate functions, and we are convinced that we'll be able to deliver efficiencies that will meet or exceed these savings."

New Capital Structure

In conjunction with the merger, AmerisourceBergen realigned its capital structure, issuing $500 million of 8.125 percent senior notes and retiring the tendered bonds of its subsidiary, PharMerica. The tender offer for the PharMerica bonds expires today. The Company also obtained a new $1.3 billion credit facility, comprised of a $300 million term loan and a $1 billion revolving credit facility.

Proceeds from the new notes will be used together with proceeds from the new credit facility to repay AmeriSource's and Bergen's existing senior secured credit facilities, to pay fees and expenses associated with the merger, to repurchase or repay certain of Bergen's other indebtedness, and for general corporate purposes such as working capital and capital expenditures.

AmerisourceBergen

AmerisourceBergen is the largest pharmaceutical services company in the United States dedicated solely to the pharmaceutical supply chain. It is the leading distributor of pharmaceutical products and services to the hospital systems/acute care market, alternative care facilities, and independent community pharmacies.

The Company is also a leader in the institutional pharmacy marketplace. With approximately $36 billion in annualized operating revenues, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people serving over 25,000 customers.

FORWARD-LOOKING STATEMENTS

This press release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include statements addressing future financial and operating results of AmerisourceBergen and the benefits and other aspects of the merger. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the risk that the businesses of AmeriSource and Bergen Brunswig will not be integrated successfully; failure to obtain and retain expected synergies; and other economic, business, competitive and/or regulatory factors affecting the business of AmerisourceBergen generally. More detailed information about these factors is set forth in AmeriSource's and Bergen Brunswig's filings with the Securities and Exchange Commission, including each of their Annual Reports on Form 10-K for fiscal 2000, their most recent quarterly reports on Form 10-Q, and their joint proxy statement-prospectus dated August 1, 2001. AmerisourceBergen, AmeriSource and Bergen Brunswig are under no obligation to (and expressly disclaim any such obligation to) update or alter their forward-looking statements whether as a result of new information, future events or otherwise.

Return to headlines

Added To S&P 500 Index

VALLEY FORGE, Pa. & ORANGE, Calif., Aug 28, 2001-- Aug. 28, 2001 AmeriSource Health Corporation (NYSE: AAS) and Bergen Brunswig Corporation (NYSE: BBC) today announced that AmerisourceBergen Corporation (NYSE: ABC), the new company which will be formed by the merger of AmeriSource and Bergen Brunswig, will be added to the Standard & Poor's 500 Index after the close of trading on Wednesday August 29, 2001.

The transaction remains subject to shareholder approval and each company has scheduled a special shareholders' meeting for approval of the merger on Wednesday, August 29, 2001. On March 19, 2001, AmeriSource and Bergen Brunswig announced that they had entered into a merger agreement to create a new company named AmerisourceBergen Corporation. Under the terms of the agreement, each share of Bergen Brunswig common stock will be converted into 0.37 shares of AmerisourceBergen common stock and each share of AmeriSource common stock will be converted into one share of AmerisourceBergen common stock.

About AmeriSource

AmeriSource Health Corporation, with approximately $14 billion in annualized operating revenue, is a leading distributor of pharmaceutical and related healthcare products and services, and the industry's largest provider of pharmaceuticals to acute care/health systems customers. Headquartered in Valley Forge, PA, the Company serves its base of about 15,000 customer accounts through a national network of 22 strategically located drug distribution facilities. For news and additional information about the Company, visit its web site at www.amerisource.com.

About Bergen Brunswig Bergen Brunswig Corporation, headquartered in Orange County, California, is a leading supplier of pharmaceuticals and specialty healthcare products as well as information management solutions and consulting services. Bergen's customers include the nation's healthcare providers (hospitals, nursing homes, physicians), drug stores, manufacturers and patients. Through its subsidiary companies, Bergen provides product distribution, logistics, pharmacy management programs, and Internet fulfillment strategies designed to reduce costs and improve patient outcomes across the entire healthcare spectrum. Bergen Brunswig press releases are available on the Company's web site at www.bergenbrunswig.com.

Forward-Looking Statements

The matters discussed in this press release may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. Certain forward-looking statements can be identified by the use of forward-looking terminology such as `believes', expects', `may', `will', `could', `should', `seeks', `approximately', `intends', `plans', `estimates', or `anticipates', or the negative thereof or another comparable terminology, and statements addressing the timing, benefits and other aspects of the proposed merger. The following factors, among others could cause actual results to differ materially from those described in the forward-looking statements: inability to obtain or meet conditions imposed for government approvals for the transaction; failure of stockholders of AmeriSource and Bergen to approve the merger; the risk that the businesses of AmeriSource and Bergen will not be integrated successfully; failure to obtain and retain expected synergies; and other economic, business, competitive and/or regulatory factors affecting the business of AmeriSource and Bergen generally. The inclusion of forward-looking statements in this press release by AmeriSource and Bergen should not be regarded as representations by the companies that the plans of AmeriSource and Bergen or AmerisourceBergen will be achieved. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AmeriSource and Bergen assume no obligation to update the information contained in this press release.

Additional Information

In connection with their proposed merger, AmeriSource and Bergen Brunswig filed a joint proxy statement/prospectus with the Securities and Exchange Commission. Investors and security holders are advised to read the joint proxy statement/prospectus because it contains important information. Investors and security holders may obtain a free copy of the joint proxy statement/prospectus and other documents filed by AmeriSource and Bergen Brunswig at the Securities and Exchange Commission's web site at www.sec.gov. The joint proxy statement/prospectus and such other documents may also be obtained for free from AmeriSource or from Bergen Brunswig by directing such request to AmeriSource Health Corporation, General Counsel, 1300 Morris Drive, Suite 100, Chesterbrook, Pennsylvania 19087-5594, Telephone: 610/727-7000; or to Bergen Brunswig Corporation, Attention: Corporate Secretary, 4000 Metropolitan Drive, Orange, California 92868-3510, Telephone: 714/385-4000.

Return to headlines